Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.738 | Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊教授 |
| 2021.740 | Fluid Overload as the Cause of Gut Permeability Barrier Dysfunction in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.163 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.170 | Development of a novel risk score for the prognosis of IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2022.125 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2023.363 | Modified Creatinine Index as a Non-Invasive Tool for the Monitoring of Muscle Mass in Peritoneal Dialysis |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2021.367 | The Prognostic Role of Volume Overload in New Peritoneal Dialysis Patients |
Prof Szeto Cheuk Chun 司徒卓俊 |
| 2023.641 | Peritoneal Leukocyte Load as Predictor of Peritoneal Membrane Failure |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.566 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease | Prof. SZETO Cheuk Chun |
| 2008.257 | Monitoring of Urinary Messenger RNA Expression for the Prediction of Flare in Systemic Lupus Erythematosus | Prof Szeto Cheuk Chun |
| 2010.376 | Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis | Prof. SZETO Cheuk Chun |
| 2010.375 | Circulating Bacterial-Derived DNA Fragments in Peritoneal Dialysis | Prof. SZETO Cheuk Chun |
| 2010.173 | Relation Between Intra-Renal Cytokine Expression and Histological Class of Lupus Nephritis | Prof. SZETO Cheuk Chun |
| 2012.050 | Long-Term Outcome of Biopsy-Proven Minimal-Change Nephrotic Syndrome in Adult | Prof. SZETO Cheuk Chun |
| 2012.048 | Long-Term Outcome of Biopsy-Proven Minimal-Change Nephrotic Syndrome in Children | Prof. SZETO Cheuk Chun |
| 2009.188 | The Effect of Neutral Peritoneal Dialysis Solution with Minimal Glucose-Degradation-Product on the Body Composition - A Cross-Sectional Study | Prof. SZETO Cheuk Chun |
| 2008.378 | Acute-on-Chronic Renal Failure: Indenticiation of Urinary Biomarkers for the Prediction of Reversibility | Dr. SZETO Cheuk Chun |
| 2012.541 | Circulating Mitochondrial-Derived DNA Fragments: A Possible Factor in the Pathophysiology of Systemic Inflammation and Cardiovascular Disease in Chronic Kidney Disease? | Prof. SZETO Cheuk Chun |
| 2012.311 | Patients Who Default From Follow-up at Renal Specialist Clinic: Characteristics and Prognostic Implications | Prof. SZETO Cheuk Chun |
| 2011.253 | Relation Between microRNA Expression in Peritoneal Dialysis Effluent and Peritoneal Transport Characteristics | Prof. SZETO Cheuk Chun |
| 2008.276 | Genetic Determinants of Peritoneal Transport Characteristics, Peritonitis and Cardiovascular Risk for Chronic Peritoneal Dialysis Patients | Prof. SZETO Cheuk Chun |
| 2013.253 | Intra-Renal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis | Prof. Szeto Cheuk Chun |
| 2012.542 | Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis | Prof. SZETO Cheuk Chun |
| 2010.405 | The effect of using ultrapure water for hemodialysis on the circulating levels of bacterial endotoxin and proinflammatory cytokines | Prof. SZETO Cheuk Chun |
| 2009.359 | Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis | Prof. SZETO Cheuk Chun |
| 2009.356 | Circulating Bacterial-Derived DNA Fragments and Markers of Iinflammation in Peritoneal Dialysis Patients | Prof. SZETO Cheuk Chun |
| 2010.186 | In-Depth Analysis of Patients Who Missed the Appointment of general Medical Clinic | Prof. SZETO Cheuk Chun |
| 2009.246 | Outcome of Hemodialysis Patients Who had Failed Peritoneal Dialysis | Prof. SZETO Cheuk Chun |
| 2013.530 | Determining the Role of microRNA in Peritoneal Fibrosis by ex vivo Mesothelial Cell Culture from Peritoneal Dialysis Patients | Professor Szeto Cheuk Chun |
| 2012.122 | The role of Extracellular Microvesicle miR-21 as a Mediator Of Progressive Renal Tubulointerstital Fibrosis | Prof. Szeto Cheuk Chun |
| 2010.164 | TRK-100STP Phase Iib/III Clinical Study Protocol | Prof. SZETO Cheuk Chun |
| 2014.242 | Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients | Professor Szeto Cheuk Chun |
| 2010.278 | Hemoglobin Variability in Chinese Pre-Dialysis CKD Patients Not Reciving Erythropoietin | Prof. SZETO Cheuk Chun |
| 2013.532 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients | Professor SZETO Cheuk Chun |
| 2009.355 | The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition | Prof. SZETO Cheuk Chun |
| 2013.564 | A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis | Prof. SZETO Cheuk Chun |
| 2017.368 | Urinary Sediment RNA Profile for the Prediction of Therapeutic Response in Lupus Nephritis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.480 | Urinary RNA Levels as Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.564 | Urinary Podocyte mRNA as a Prognostic Marker of Diabetic Nephropathy | Prof. SZETO Cheuk Chun |
| 2016.483 | Cost-effectiveness analysis of screening of BK virus-associated nephropathy using urine cytology and serum quantitative polymerase chain reaction |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.352 | Long Non-Coding RNA (IncRNA) in the Urinary Sediment of Patients with Chronic Kidney Disease | Professor SZETO Cheuk Chun |
| 2014.482 | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | Prof. SZETO Cheuk Chun |
| 2015.228 | Relation Between Peritoneal Dialysis Effluent microRNA Level and Longitudinal Change in Peritoneal Transport Characteristics |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.721 | Urinary Mitochondrial DNA Level as a Biomarker of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.327 | The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients with High Dialysis Effluent Bacterial DNA Fragment Levels |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.250 | Genetic Determinants of Peritoneal Transport Characteristics and Cardiovascular Diseases for Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2017.420 | Urinary miRNA profile as the biomarker of IgA nephropathy |
Prof Szeto Cheuk Chun 司徒卓俊 |
| 2017.648 | Extracellular Mitochondrial DNA Released by Peritoneal Mesothelial Cell as the Trigger of Macrophage Activation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.582 | Pharmacological Treatment of Mitochondrial Dysfunction in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.283 | The role of Activating Transcription Factor 5 (ATF5) for mitochondrial protection in diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
Page 198 of 262.